Ansaid Articles
7th year of rising profit for Kaken Pharma
5 June 2009
Myriad discontinues MPC-7869 in cancer
15 January 2007
Headlines 25 years ago this week....
9 October 2006
NicOx's HCT1026 slows bone loss in osteopenia
18 July 2005
Aesica secures major Alzheimer's contract
7 February 2005
Management buyout of BASF pharma site
13 September 2004
Myriad Genetics posts record sales
23 August 2004
NicOx' HCT 1026 shows promise in AD
19 April 2004
Myriad and Mayo Clinic sign deal
21 July 2003
Myriad starts Phase II trial of MPC-7869
7 July 2003
Caraco expects $35M revenues in 2003
24 February 2003
Caraco gets US OK for metformin/tramadol
4 February 2002
UK MCA proposes POM-to-P switches
16 August 2001
NicOx reports progress with topical anti-inflammtory
30 November 2000
NicOx urticaria drug showing early promise
5 July 2000
Encore sees promise with R-flurbiprofen
18 April 2000
NicOx begins Phase IIa with HCT-1026
20 December 1999
NicOX begins Ph IIa HCT-1026 trial
29 July 1999
NicOx reveals promising data
14 July 1999
Italy's New Prontuario Bars 900 Drug Products
15 July 1996
Global Rx-To-OTC Switching Study
27 November 1995
Teva gets approval for flurbiprofen and diltiazem
19 June 1995
BASF Purchase Of Boots Concluded
10 April 1995
NSAID Debate Continues Apace In USA
13 March 1995
End Of Year Encouraging For US Companies
6 February 1995
World Immunology, Rheumatology Markets
28 November 1994
Good Half-year For Boots But No News On Pharma
7 November 1994
Theramex Launches Antadys In France
3 October 1994
MYLAN RECEIVES GENERIC APPROVAL IN USA
4 July 1994
MIGRAINE MARKET SET TO BLOSSOM
21 February 1994
MUSCULOSKELETAL MARKET TO DECLINE
6 December 1993
HOECHST CELANESE ACQUIRES US GENERICS CO
25 October 1993
EXTENSION TO JAPANESE FORMULARY
11 October 1993
BOOTS CONSIDERS DRUG DIV FUTURE
2 August 1993
MANOPLAX DEFEATED BUT BOOTS SHARES RALLY
26 July 1993
FLURBIPROFEN AND CONVULSIONS
5 July 1993
UPJOHN PACT WITH GENEVA EXTENDED
5 April 1993
RISK YEARS AHEAD FOR UPJOHNFOR UPJOHN
22 March 1993
US 4th QTR SHOWS NOT ALL COMPANIES STRONG
15 February 1993
GENERIC HALCION AND XANAX IN USA
1 February 1993
NEW CHEMICAL ENTITIES LAUNCHED IN 1992
1 February 1993
FLURBIPROFEN IN MIGRAINE
25 January 1993
US OTC ANALGESICS - A 1992 RETROSPECTIVE
4 January 1993
ALLERGAN DATA INADEQUATE
9 November 1992
SALES RISE BUT PROFITS POOR FOR FIRMS IN JAPAN
29 June 1992
UPJOHN'S GLYNASE APPROVED IN USA
27 April 1992
PATENT EXTENSION SOUGHT BY UPJOHN
20 April 1992
UPJOHN UPDATES ON R&D PROGRESS
13 April 1992
VOLUME GROWTH FOR US DRUGMAKERS
9 March 1992
RECORD 4TH QTR FROM US DRUG COMPANIES
10 February 1992
DECEMBER US APPROS REVIEWED
20 January 1992
ANALGESICS IN THE USA -- AN OPEN DOOR FOR P&G?
6 January 1992
Showing 1-55 of 55 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
